Pliant Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
PLRX Nasdaq 2830 pliantrx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Pliant Therapeutics, Inc.

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results - May 11th, 2026 2:05 pm
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference - May 6th, 2026 6:30 am
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors - Apr 30th, 2026 6:30 am
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting - Apr 18th, 2026 11:31 am
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting - Mar 18th, 2026 7:00 am
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results - Mar 11th, 2026 2:05 pm
Pliant Therapeutics Pivots to Oncology, Highlights Early PLN-101095 Responses at Oppenheimer Conference - Mar 1st, 2026 8:39 am
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference - Feb 23rd, 2026 6:00 am
Enhanced Genomics Appoints Dr Katerina Leftheris to Its Board of Directors - Jan 9th, 2026 7:10 am
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors - Dec 4th, 2025 5:30 am
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference - Dec 1st, 2025 6:30 am
Idiopathic Pulmonary Fibrosis Research Report 2025-2035: Market Led by Roche, Pliant Therapeutics, Bristol-Myers Squibb, and Vicore as Next-Gen Antifibrotics and Targeted Therapies Drive Innovation - Nov 18th, 2025 8:06 am
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results - Nov 6th, 2025 2:05 pm
3 Promising Penny Stocks With Market Caps Under $500M - Oct 17th, 2025 6:05 am
Align downgraded, NetEase upgraded: Wall Street's top analyst calls - Oct 10th, 2025 7:36 am
Penny Stocks To Watch With Market Caps Under $700M - Sep 8th, 2025 12:04 pm
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - Aug 7th, 2025 2:05 pm
3 Promising Penny Stocks With Market Caps Under $200M - Jul 15th, 2025 12:09 pm
Pliant halts bexotegrast development for IPF after trial results - Jun 30th, 2025 5:43 am